Last updated: September 9, 2026
Chorionic gonadotropin is a mature fertility biologic with stable clinical demand, limited patent protection, and fragmented commercial economics. The market divides between urinary-derived human chorionic gonadotropin, including Pregnyl and Novarel, and recombinant choriogonadotropin alfa, marketed as Ovidrel. Fertility treatment is the core revenue driver. Male hypogonadotropic hypogonadism and cryptorchidism are smaller approved or historical use segments, while weight-loss use is unauthorized and does not represent a durable pharmaceutical market.
Standalone product revenue is not publicly disclosed by the principal manufacturers. The commercial outlook is therefore best assessed through fertility-cycle volumes, product availability, reimbursement, pricing, manufacturing constraints, and competition rather than reported brand sales.
What is chorionic gonadotropin and how is the market segmented?
Chorionic gonadotropin is a glycoprotein hormone that mimics luteinizing hormone. It binds the luteinizing hormone/chorionic gonadotropin receptor and induces ovulation or stimulates testosterone production, depending on the patient population and treatment protocol.
| Segment |
Representative product |
Source |
Main use |
Commercial position |
| Urinary hCG |
Pregnyl |
Human urine-derived |
Ovulation induction, male hypogonadism, cryptorchidism |
Established, price-sensitive |
| Urinary hCG |
Novarel |
Human urine-derived |
Ovulation induction, male hypogonadism, cryptorchidism |
Established, supply-sensitive |
| Recombinant hCG |
Ovidrel |
Recombinant choriogonadotropin alfa |
Ovulation induction in assisted reproduction |
Premium convenience product |
| Compounded or imported hCG |
Various |
Variable |
Fertility and off-label use |
Regulatory and quality risk |
| Long-acting hCG analogues |
None widely commercialized in the U.S. |
Not applicable |
Not applicable |
No material U.S. market |
Urinary products are supplied as lyophilized powder that is reconstituted before administration. Ovidrel is supplied as a prefilled recombinant product, reducing preparation steps and exposure to variability in urinary-source manufacturing.
The largest commercial use is controlled ovulation induction in patients undergoing intrauterine insemination or in vitro fertilization. hCG can also be used to trigger final follicular maturation after stimulation with gonadotropins. In men, hCG is used to stimulate endogenous testosterone production in selected hypogonadal patients. [1][2][3]
How large is the chorionic gonadotropin market?
No major manufacturer reports global chorionic gonadotropin revenue as a separate line item. Market estimates that aggregate hCG, recombinant hCG, fertility gonadotropins, and broader reproductive-health products are not directly comparable.
The market has four economic characteristics:
- Demand is tied to fertility-treatment volume rather than general pharmaceutical consumption.
- Product choice is influenced by clinic protocols, payer coverage, patient out-of-pocket cost, and supply.
- Ovidrel can obtain a premium because of recombinant production and administration convenience.
- Urinary hCG products compete primarily on availability and price.
U.S. fertility demand has expanded over the long term because of delayed childbearing, increased use of assisted reproductive technology, broader access to fertility clinics, and greater insurance coverage in some jurisdictions. The number of assisted reproductive technology cycles reported in the United States has remained commercially significant, creating a recurring demand base for ovulation-trigger products. [4]
The market is still small relative to major biologic categories such as insulin, monoclonal antibodies, or erythropoietin. It is also more fragmented because hCG is often purchased as one component of a broader fertility protocol that includes follicle-stimulating hormone, luteinizing hormone, gonadotropin-releasing hormone analogues, progesterone, and estrogen.
What is the financial trajectory for chorionic gonadotropin products?
The financial trajectory is mature and volume-driven, with limited patent-based pricing power.
Revenue drivers
The principal positive drivers are:
- Growth in assisted reproductive technology cycles.
- Higher use of ovulation induction and intrauterine insemination.
- Greater adoption of fertility treatment among older patients.
- Clinic preference for prefilled recombinant products.
- Supply disruptions affecting competing urinary products.
- Expansion of insurance coverage for infertility treatment.
Revenue constraints
The main constraints are:
- Generic and therapeutic substitution pressure.
- Limited differentiation between urinary hCG products.
- Reimbursement restrictions and high patient cost sharing.
- Reproductive-health policy changes.
- Manufacturing complexity for urinary-derived products.
- Lack of direct-to-consumer demand for approved indications.
- Off-label use being excluded from durable reimbursement assumptions.
Ovidrel is positioned to preserve higher net pricing than urinary hCG because it offers a ready-to-use recombinant presentation. That premium is vulnerable when payers require lower-cost urinary alternatives or when clinics standardize protocols around a particular supplier.
Pregnyl and Novarel have lower technological differentiation. Their financial performance is more exposed to manufacturing continuity, inventory levels, shortages, contract supply, and distributor pricing.
A realistic base case is low-single-digit market growth in line with fertility treatment volume, offset by price erosion in mature products. Upside would require sustained fertility-cycle expansion, improved coverage, or supply-driven migration toward recombinant hCG. Downside would result from reimbursement reductions, regulatory action against compounded products, or increased use of alternative ovulation-trigger protocols.
What patents protect chorionic gonadotropin products?
The core composition-of-matter patent estate for human chorionic gonadotropin is effectively historical. hCG was identified and commercialized decades ago, and the foundational rights covering the hormone, urinary extraction, and conventional injectable use have expired.
| Product or technology |
Patent position |
Current commercial relevance |
| Human chorionic gonadotropin molecule |
Foundational rights expired |
No meaningful composition exclusivity |
| Conventional urinary extraction |
Historical process rights expired or commercially weak |
Manufacturing know-how remains relevant |
| Injectable urinary hCG |
Legacy product rights expired |
Competes on supply, quality, and price |
| Recombinant choriogonadotropin alfa |
Original platform and product rights expired or near-expired depending on jurisdiction and claim |
No clear durable U.S. composition moat |
| Prefilled syringe presentation |
Potential historical device or formulation rights |
Limited ability to block all substitutes |
| Fertility method-of-use claims |
Narrow and protocol-dependent |
Low barrier to alternative regimens |
Public FDA product materials identify the products and approved uses, but they do not indicate a current, broad U.S. patent barrier comparable to the patent estates surrounding newer biologics. [1][2][3]
The commercially relevant protection has shifted from classic patent exclusivity to operational know-how. This includes:
- Maintaining potency and purity during urinary collection and purification.
- Controlling glycoform distribution.
- Achieving consistent batch release.
- Preserving sterility in lyophilized injectables.
- Managing cold-chain logistics.
- Qualifying reliable urine-source networks.
- Complying with current biologics manufacturing standards.
These factors can delay or discourage competitors without creating legal exclusivity.
When does chorionic gonadotropin lose exclusivity?
For the legacy urinary hCG products, effective exclusivity has already expired. Pregnyl and Novarel are mature products with no apparent remaining market exclusivity based on the age of their approvals and the absence of a durable modern patent barrier.
Ovidrel's FDA approval also dates to the mature recombinant fertility-drug era. Any original regulatory exclusivity and principal product patents are no longer sufficient to prevent competition across the hCG category. The absence of a direct substitute with identical formulation and device characteristics can preserve commercial value, but that is different from enforceable exclusivity.
The relevant distinction is:
- Legal exclusivity: the ability to block approval or sale through patents or FDA exclusivity.
- Commercial differentiation: the ability to command a premium because of convenience, reliability, or clinical familiarity.
Chorionic gonadotropin now relies mainly on commercial differentiation.
What is the Orange Book status of chorionic gonadotropin?
The FDA Orange Book is most relevant to drug products approved under the Federal Food, Drug, and Cosmetic Act. It does not function as a complete patent database for biologics or biologic-like products.
For chorionic gonadotropin, the principal regulatory issue is product classification:
- Urinary hCG products are legacy prescription injectable products with long-established FDA approvals.
- Recombinant choriogonadotropin alfa is a recombinant protein product approved for fertility use.
- The applicable approval pathway and reference-product status must be evaluated product by product.
- Orange Book listing alone does not establish a complete patent position for a biologic or protein product. [5]
A current diligence review should distinguish between FDA-listed product information, Orange Book patents, Purple Book reference-product information, and USPTO patent records. Treating the Orange Book as the sole source of hCG patent risk would understate or misclassify the relevant rights.
Are there Paragraph IV challenges to chorionic gonadotropin?
No widely reported, market-defining Paragraph IV campaign has shaped the U.S. chorionic gonadotropin market in the manner seen with high-value small molecules.
This is commercially logical. A Paragraph IV strategy is most attractive when:
- The reference product has substantial remaining sales.
- A generic can be approved through an efficient pathway.
- The formulation and active ingredient are readily replicated.
- The challenger can obtain meaningful market share.
- Patent litigation can be resolved before the opportunity expires.
Mature urinary hCG products provide limited patent value. Ovidrel presents greater technical and regulatory complexity because a recombinant protein and prefilled delivery system may not map cleanly onto a conventional ANDA strategy.
A competitor could pursue a 505(b)(2), biosimilar, interchangeable biosimilar, or other product-specific route depending on FDA classification and development strategy. The economics remain constrained by the relatively modest market size and established alternatives.
Is there biosimilar risk for Ovidrel and other hCG products?
Biosimilar risk is theoretically possible but commercially moderate rather than immediate.
Ovidrel is a recombinant glycoprotein, making analytical comparability more complicated than for a simple synthetic molecule. Relevant attributes include:
- Amino-acid sequence.
- Protein folding.
- Subunit structure.
- Glycosylation pattern.
- Potency.
- Impurity profile.
- Aggregation.
- Stability.
- Device performance.
A biosimilar applicant would need to establish a sufficiently robust analytical package and satisfy FDA requirements for clinical and pharmacologic comparability. The cost and development burden may be difficult to justify against a relatively narrow fertility market.
Urinary hCG presents a different challenge. The product is biologically sourced and may have batch-to-batch attributes related to purification and glycoforms. A competitor can still enter, but manufacturing consistency and regulatory comparability remain important barriers.
The most likely competitive threat is not a rapid wave of interchangeable biosimilars. It is gradual substitution among urinary hCG products, recombinant products, imported products, and alternative fertility protocols.
What formulation patents protect chorionic gonadotropin?
Formulation protection is limited. Conventional hCG products generally use established excipients, lyophilized presentations, and reconstitution systems. These features are technically important but usually provide narrow claim scope.
Potential formulation or device claims could address:
- Stabilized hCG compositions.
- Reduced aggregation.
- Improved reconstitution.
- Multi-dose or single-dose packaging.
- Prefilled syringe delivery.
- Needle or injection-device configurations.
- Extended refrigerated or room-temperature stability.
Such claims would not necessarily block a competitor using a different excipient system, vial configuration, or device. The strongest commercial protection historically has come from Ovidrel's integrated recombinant product and prefilled presentation, not from a broad formulation monopoly.
Which companies compete in the chorionic gonadotropin market?
The commercial landscape includes branded manufacturers, specialty distributors, fertility pharmacies, and compounders.
| Company or channel |
Product or role |
Competitive factor |
| Merck KGaA / EMD Serono |
Ovidrel |
Recombinant source, prefilled syringe, fertility-clinic adoption |
| Ferring Pharmaceuticals |
Novarel |
Urinary hCG, established fertility channel |
| Organon or successor commercial channels |
Pregnyl |
Legacy brand recognition and distribution |
| Specialty pharmacies |
Branded and authorized products |
Availability, reimbursement support, fulfillment |
| Compounding pharmacies |
Compounded hCG |
Price and access, with greater regulatory scrutiny |
| International suppliers |
Various hCG products |
Lower pricing, regulatory and supply-chain risk |
Corporate ownership and distribution arrangements can change without altering the underlying product patent position. The key commercial question is whether a supplier controls a reliable product source and maintains FDA-compliant manufacturing.
What patent litigation and settlement agreements affect chorionic gonadotropin?
No major, publicly established U.S. patent litigation campaign currently defines the chorionic gonadotropin market. There is also no widely recognized settlement framework comparable to the settlements associated with blockbuster small-molecule products.
Litigation risk is more likely to arise from:
- Manufacturing quality disputes.
- Product liability.
- False advertising.
- Compounding and distribution practices.
- Trademark or trade-dress claims.
- FDA enforcement involving unapproved or adulterated products.
- Contract disputes between manufacturers, distributors, and fertility clinics.
A competitor seeking to enter with a recombinant or complex injectable product would face regulatory and manufacturing questions before patent litigation became the central barrier.
What FDA regulatory issues affect chorionic gonadotropin?
The FDA has approved hCG products for specific indications, including ovulation induction and selected male reproductive disorders. It has not approved hCG as a weight-loss treatment. FDA has warned that products promoted for weight loss, bodybuilding, or similar purposes do not create a lawful substitute for approved hCG therapy. [6]
Regulatory risks include:
- Misbranding for unapproved weight-loss claims.
- Compounding outside applicable statutory conditions.
- Sterility failures.
- Inaccurate potency.
- Inadequate quality systems.
- Unapproved imported products.
- Inadequate adverse-event reporting.
- Promotional claims that exceed the approved label.
These risks can support branded demand when physicians and clinics require FDA-approved supply. They can also reduce the addressable market for low-cost compounded products if enforcement increases.
What generic launch scenarios exist for chorionic gonadotropin?
Three launch scenarios are commercially plausible.
Scenario 1: Urinary hCG price competition
A manufacturer enters with a conventional urinary hCG injectable. The product competes on price, distributor access, and supply reliability. This is the lowest-risk commercial scenario but also the lowest-margin opportunity.
Scenario 2: Recombinant hCG competitor
A company develops a recombinant hCG product with a new presentation or delivery device. This could compete directly with Ovidrel but would require more extensive analytical, clinical, manufacturing, and regulatory work.
Scenario 3: Alternative ovulation-trigger product
A manufacturer offers a competing trigger based on a different hormone or protocol. This does not challenge hCG patents directly but can reduce hCG utilization in selected fertility regimens.
The first scenario is the most likely. The second has higher technical value but weaker market economics. The third creates the greatest long-term utilization risk for hCG manufacturers because it changes treatment protocols rather than merely substituting products.
How strong is the chorionic gonadotropin patent estate?
The patent estate is weak as a blocking asset and moderate as a manufacturing asset.
| Dimension |
Assessment |
| Composition-of-matter protection |
Expired |
| Core method-of-use protection |
Expired or narrow |
| Formulation protection |
Narrow |
| Device protection |
Potentially narrow and design-around capable |
| Manufacturing know-how |
Meaningful |
| Regulatory complexity |
Moderate |
| Supply-chain barriers |
Moderate to high for urinary products |
| Litigation leverage |
Low |
| Commercial brand value |
Moderate in fertility clinics |
| Generic or biosimilar vulnerability |
Moderate, but entry economics limit intensity |
Investors should not underwrite chorionic gonadotropin on patent life. The value resides in manufacturing control, supply reliability, clinic relationships, reimbursement access, and product convenience.
What revenue exposure do manufacturers have?
Revenue exposure is usually limited at the corporate level because hCG products are part of broader fertility or specialty-pharmaceutical portfolios. A supply disruption can still have a disproportionate effect on a smaller manufacturer or specialty distributor.
The highest exposure is concentrated in:
- Fertility-focused manufacturers.
- Specialty pharmacies.
- Distributors carrying a narrow injectable portfolio.
- Clinics that rely on one hCG supplier.
- Manufacturers with limited urinary-source redundancy.
For large pharmaceutical companies, hCG is unlikely to be a major earnings driver. For specialized fertility companies, the product can support recurring revenue and customer retention even when its absolute sales are modest.
How does chorionic gonadotropin compare with competing fertility drugs?
| Product class |
Primary role |
Patent position |
Commercial outlook |
| hCG |
Ovulation trigger and luteal support in selected protocols |
Mature, weak |
Stable but price-sensitive |
| Recombinant FSH |
Follicular stimulation |
Stronger historical estates, some biosimilar pressure |
Larger and more valuable market |
| Urinary FSH/hMG |
Follicular stimulation |
Mature |
Competes on price and supply |
| GnRH agonists and antagonists |
Cycle control and prevention of premature ovulation |
Product-specific |
Protocol-driven demand |
| Progesterone |
Luteal support |
Mature |
Broad generic competition |
| Recombinant LH |
Follicular stimulation in selected patients |
More specialized |
Narrower market |
hCG is less valuable than the major stimulation products because it is generally used as a discrete trigger rather than throughout the stimulation cycle. It remains clinically important, but its revenue ceiling is lower.
Key Takeaways
- Chorionic gonadotropin is a mature fertility biologic with stable recurring demand.
- The market includes urinary hCG products such as Pregnyl and Novarel and recombinant choriogonadotropin alfa, marketed as Ovidrel.
- Core composition patents and foundational exclusivity have expired.
- No broad, durable U.S. patent moat appears to protect the category.
- Ovidrel retains commercial differentiation through recombinant production and a prefilled presentation.
- Urinary hCG is more exposed to supply interruptions, manufacturing constraints, and price competition.
- Biosimilar and complex injectable entry is technically possible but may be limited by market size and development economics.
- No major Paragraph IV campaign or patent settlement currently defines the market.
- FDA risk is concentrated in compounded, imported, misbranded, and weight-loss-promoted hCG products.
- Financial performance depends more on fertility-cycle growth, reimbursement, manufacturing reliability, and clinic relationships than on patent exclusivity.
- The most defensible investment thesis is operational rather than patent-driven.
FAQs
Is chorionic gonadotropin still patent protected?
The core hCG molecule and traditional injectable uses are no longer protected by meaningful foundational patent exclusivity. Narrow formulation, device, or process claims may exist, but they are unlikely to block the entire category.
Is Ovidrel a biosimilar?
Ovidrel is a recombinant choriogonadotropin alfa product, not a biosimilar. A future competitor could potentially pursue a biosimilar or another complex-biologic pathway, subject to FDA classification and comparability requirements.
Can hCG be sold for weight loss?
FDA-approved hCG products are not approved for weight loss. Promotional or compounded products marketed for that purpose create regulatory and enforcement risk. [6]
Which is cheaper, Ovidrel or urinary hCG?
Urinary hCG is generally positioned as the lower-cost option, while Ovidrel can command a premium for recombinant production and its ready-to-use prefilled format. Actual patient cost depends on payer coverage, pharmacy channel, and fertility-clinic protocol.
What is the largest commercial risk for hCG manufacturers?
The largest risk is not patent expiration. It is substitution caused by price pressure, unreliable supply, manufacturing deficiencies, changes in fertility protocols, and reimbursement restrictions.
References
- U.S. Food and Drug Administration. (2023). Ovidrel (choriogonadotropin alfa) prescribing information.
- U.S. Food and Drug Administration. (2023). Novarel (chorionic gonadotropin) prescribing information.
- U.S. Food and Drug Administration. (2023). Pregnyl (chorionic gonadotropin) prescribing information.
- Centers for Disease Control and Prevention. (2023). 2021 assisted reproductive technology fertility clinic and national summary report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2011). HCG products marketed for weight loss are not approved by FDA.
